

Amendment Statement of Principles concerning HYPOGONADISM (Reasonable Hypothesis) (No. 51 of 2022)

The Repatriation Medical Authority determines the following Amendment Statement of Principles under subsections 196B(2) and (8) of the *Veterans' Entitlements Act* 1986.

Dated 29 April 2022

The Common Seal of the Repatriation Medical Authority was affixed to this instrument at the direction of:

Professor Terence Campbell AM Chairperson

Contents

1	Name	3
2	Commencement	3
3	Authority	3
4	Amendment	3

1 Name

This is the Amendment Statement of Principles concerning *hypogonadism* (Reasonable Hypothesis) (No. 51 of 2022).

2 Commencement

This instrument commences on 30 May 2022.

3 Authority

This instrument is made under subsections 196B(2) and (8) of the *Veterans' Entitlements Act 1986*.

4 Amendment

The Statement of Principles concerning *hypogonadism (Reasonable Hypothesis)* (No. 73 of 2021) (Federal Register of Legislation No. F2021L00619) is amended in the following manner:

Section	Amendment
Schedule 1 – Dictionary	Replace the existing definition of "immune checkpoint inhibitor" with the following:
	immune checkpoint inhibitor means a form of cancer immunotherapy that uses monoclonal antibodies targeting the immune checkpoint proteins. Examples include ipilimumab, tremelimumab, nivolumab and pembrolizumab.